Kagan Karl Oliver, Hoopmann Markus, Sonek Jiri
Department of Women's Health, University of Tübingen, Calwerstrasse 7, 72076, Tübingen, Germany.
Fetal Medicine Foundation USA, Dayton, OH, USA.
Arch Gynecol Obstet. 2025 May;311(5):1233-1240. doi: 10.1007/s00404-025-08021-7. Epub 2025 Apr 9.
Despite the widespread use of cell-free DNA in screening for trisomy 21, soft markers continue to be assessed in the second trimester, leading to confusion about how they affect the risk of trisomy 21, especially after an earlier screening test such as cell-free DNA screening. In this review, we provide an overview of commonly used second trimester soft markers, explain how they can be used to calculate the risk for trisomy 21, and discuss what other chromosomal or structural abnormalities might be associated with these markers. We especially focus on pathogenic copy number variants as these, in aggregate, are common and are very difficult to detect using cfDNA or even standard karyotyping.
尽管游离DNA在21三体综合征筛查中被广泛应用,但孕中期仍在评估软指标,这导致人们对它们如何影响21三体综合征风险感到困惑,尤其是在进行了如游离DNA筛查等早期筛查试验之后。在本综述中,我们概述了常用的孕中期软指标,解释了如何利用它们计算21三体综合征的风险,并讨论了这些指标可能与哪些其他染色体或结构异常相关。我们特别关注致病性拷贝数变异,因为总体而言,它们很常见,并且使用cfDNA甚至标准核型分析都很难检测到。